Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MRVI vs SKIN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SKIN Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–5 Matrix Metrics)

SKIN Overall Winner 6-Pillar Tally: MRVI 2 – 4 SKIN Matrix Metrics: MRVI 5 – 5 SKIN

As of Nov 16, 2026, The Beauty Health Company (SKIN) is the stronger overall head-to-head candidate over Maravai LifeSciences Holdings, Inc. (MRVI) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MRVI carries a Unified Composite Score of 52.0/100 (HOLD) at $7.40 (N/M Forward P/E, -24.2% operating margin), whereas SKIN carries 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin).

  • Composite vs. Pillar Nuance: While MRVI currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. SKIN 34.1/100 SELL), SKIN captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (2.4% vs. -24.2% operating margin) and revenue trajectory (-2.1% vs. +10.1% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MRVI vs SKIN
MRVI NASDAQ
Maravai LifeSciences Holdings, Inc. Class A Common Stock
Pharmaceutical Preparations
$7.40
-1.86% 1D
Market Cap $2.0B
TTM Revenue $213M
Forward P/E N/M
Beta / 30D Vol 1.61β · 83% Vol
Unified Composite Score
52.0 / 100 HOLD
Tech 37.0 Fund 53.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.4 · SMA20: $7.64 · SMA50: $7.40
SKIN NASDAQ Head-to-Head Winner
The Beauty Health Company Class A Common Stock
Surgical & Medical Instruments & Apparatus
$15.05
-7.73% 1D
Market Cap $106.3M
TTM Revenue $289M
Forward P/E 106.4x
Beta / 30D Vol -14.22β · 192% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 50.0 Fund 34.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (314.8% over 20 days), RSI 67
RSI-14: 67.4 · SMA20: $12.50 · SMA50: $6.24

6-Pillar Scorecard Institutional Category Breakdown (MRVI 2 – 4 SKIN)

Columns: Metric · MRVI · SKIN
1. Valuation Multiples SKIN
Forward P/E N/M 106.4x
Trailing P/E N/M 106.4x
PEG Ratio N/M 0.93x
EV / Revenue 9.7x 0.9x
2. Growth & Scale MRVI
Revenue Growth (YoY) +10.1% -2.1%
Earnings Growth (YoY) -32.7% +0.0%
TTM Revenue (USD) $213M $289M
Market Cap $2.0B $106.3M
3. Profitability & Quality SKIN
Gross Margin 39.9% 67.2%
Operating Margin -24.2% 2.4%
Net Profit Margin -30.8% -6.3%
Return on Equity (ROE) -29.8% -30.1%
4. Balance Sheet & Cash Flow SKIN
Cash Generation (TTM) -$13M $17M
Cash Flow Margin -5.9% 5.8%
Net Cash / Leverage $103M Net Debt (0.90x D/E) $161M Net Debt (6.61x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MRVI
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 167.3% (35th %ile) 517.4% (100th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat SKIN
OpEx & R&D Intensity 64.1% of Rev ($137M) 64.8% of Rev ($187M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Household & Personal Products Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MRVI (5) vs SKIN (5)
Institutional Metric MRVI SKIN Criterion Row Edge
Market Capitalization
Scale
$2.0B $106.3M Larger Scale MRVI
Trailing P/E Ratio
Valuation
N/M 106.4x Lower Multiple SKIN
Forward P/E Ratio
Valuation
N/M 106.4x Lower Multiple SKIN
Revenue Growth (YoY)
Growth
+10.1% -2.1% Higher Growth MRVI
Operating Margin (TTM)
Profitability
-24.2% 2.4% Higher Margin SKIN
Net Profit Margin
Profitability
-30.8% -6.3% Higher Margin SKIN
Return on Equity (ROE)
Capital Efficiency
-29.8% -30.1% Higher ROE MRVI
52-Week Range Position
Momentum
70% ($3–$9) 83% ($0–$18) Stronger Trend SKIN
Beta / 30D Volatility
Risk Regime
1.61β · 83% Vol -14.22β · 192% Vol Lower Realized Risk MRVI
Unified Institutional Score
Composite Signal
52.0 / 100 (HOLD) 34.1 / 100 (SELL) Higher Composite MRVI
Trailing 12M Revenue (USD)
Operating Scale
$213M $289M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
39.9% 67.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.7x EV/Rev 0.93x PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$13M ($103M Net Debt (0.90x D/E)) $17M ($161M Net Debt (6.61x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SKIN +33.54 pp
MRVI: +8.98% · SKIN: +42.52%
3M Horizon SKIN +2379.41 pp
MRVI: +28.92% · SKIN: +2408.33%
6M Horizon SKIN +2303.77 pp
MRVI: +81.37% · SKIN: +2385.14%
1Y Horizon SKIN +930.0 pp
MRVI: +127.69% · SKIN: +1057.69%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MRVI Revenue SKIN Revenue MRVI Op. Margin SKIN Op. Margin Margin Leader
FY2019 $140M $170M 16.8% 8.1% MRVI
FY2020 $280M $120M 42.2% -14.4% MRVI
FY2021 $800M $260M 69.4% -15.4% MRVI
FY2022 $880M $370M 65.0% -7.1% MRVI
FY2023 $290M $400M -11.0% -32.9% MRVI
FY2024 $260M $330M -90.9% -20.3% SKIN
FY2025 $190M $300M -115.9% -6.9% SKIN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MRVI BREAKOUT
98d in phase · OBV DISTRIBUTION
Current IV 167.3%
IV Percentile 35th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact MRVI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SKIN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 517.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact SKIN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MRVI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.0B market capitalization and -24.2% operating margin.
OpEx & R&D Reinvestment 64.1% of Rev ($137M)
90D Engineering Disclosures 0 Published
SKIN Moat Profile Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $106.3M market capitalization and 2.4% operating margin.
OpEx & R&D Reinvestment 64.8% of Rev ($187M)
90D Engineering Disclosures 0 Published

Investor FAQ MRVI vs SKIN Key Questions & Quantitative Answers

As of Nov 16, 2026, The Beauty Health Company (SKIN) is the stronger overall head-to-head candidate over Maravai LifeSciences Holdings, Inc. (MRVI) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MRVI carries a Unified Composite Score of 52.0/100 (HOLD) at $7.40 (N/M Forward P/E, -24.2% operating margin), whereas SKIN carries 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin). Composite vs. Pillar Nuance: While MRVI currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. SKIN 34.1/100 SELL), SKIN captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (2.4% vs. -24.2% operating margin) and revenue trajectory (-2.1% vs. +10.1% YoY).

MRVI leads the Growth & Scale pillar: MRVI posts +10.1% YoY revenue growth and -32.7% YoY earnings growth on $213M TTM revenue (39.9% gross margin, -24.2% operating margin), compared with SKIN at -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), MRVI cumulative revenue shifted +35.7% while SKIN shifted +76.5%. In operating R&D and SG&A reinvestment, MRVI deploys 64.1% of Rev ($137M) (0 90-day corporate R&D disclosures) versus 64.8% of Rev ($187M) (0 disclosures) for SKIN.

SKIN screens cheaper on headline valuation multiples. MRVI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.7x EV/Revenue (-5.9% FCF margin), whereas SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRVI (-29.8% ROE) versus SKIN (-30.1% ROE) capital efficiency.

In options market volatility and institutional positioning, MRVI carries 167.3% implied volatility (35th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKOUT options structure phase (1.61β · 83% Vol realized risk). By comparison, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI) Research Suite

The Beauty Health Company Class A Common Stock (SKIN) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.